Navigation Links
Recur in Medical Technology

June 2009 Mayo Clinic Women's HealthSource Highlights Summer Skin Problems, Low Vision and Pilates

...re in the winter are most susceptible. With increasing sun exposure, this type of light sensitivity usually decreases over time. But the same rash may recur next spring after a winter without sun exposure. Prevention -- Using sunblock and limiting sun exposure can reduce the risk of PMLE. Tr...

PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference

... patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery. About C...

MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series

...elped to improve healing in these very difficult to heal leg ulcers. Leg ulcers are very burdensome for patients and their families, are painful, and recur often. With the evidence that has been accumulated for this patient population, MEDIHONEY is gaining traction on formularies as the lead dressing whe...

Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial

...er cancer followed by currently available intravesical therapy, patients typically experience a tumor recurrence rate of 40% to 85%, of which 50% will recur within the first year. The clear need for more effective treatment creates an opportunity for a therapeutic approach that improves disease-free surviv...

ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease

... patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery. About ChemoCe...

Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases

...fficacy of the drug. When you remove from the analysis patients unlikely to recur in the study time frame, the treatment effect of PI-88 as measured in the P...study will demonstrate PI-88's effect not only for those patients likely to recur within a relatively short period of time, but also for those whose chance o...

Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors

..., Vice President, Clinical Development, said, "Despite decades of research, there has been little progress in the treatment of malignant gliomas which recur after primary therapy. We are pleased to support Dr. Raizer's study of Cloretazine(R) (VNP40101M) in this patient population." Cloretazine(R) (VNP401...

Sciele Pharma Announces Successful Completion of New Sular Formulation Clinical Trial Program

...of our products are introduced, our revenues may be adversely affected. Certain of our products have experienced manufacturing issues. If the issues recur and cannot be resolved, our ability to acquire product for sale and sampling will be adversely affected. We may incur unexpected costs in integrating ...

ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007 Conference

... patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few or no options beyond surgery. About C...

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

...quo;s Disease are forms of inflammatory bowel disease, which is considered an auto-immune disorder. They are chronic diseases which, once they start, recur regularly and cannot currently be cured. Ulcerative Colitis generally affects the large intestine and Crohn’s Disease generally affects the smal...
Other Tags
(Date:7/21/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market and creator ... has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology from ... also the user using unique personal identifiers including ...
(Date:7/13/2015)... Calif. , July 13, 2015 ... developer of human interface solutions, today announced sampling ... touch and display driver integration (TDDI) product targeting ... the first to combine Synaptics , best-in-class ... proven display driver technology developed in the company,s ...
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe ... the very first small business donation to kick off the campaign for healing and ... Her legacy includes a complete line of raw, organic hair care products, as well ...
(Date:7/31/2015)... York (PRWEB) , ... July 31, 2015 , ... When ... their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) zoysia ... application in process. , To commemorate introduction of this new type of sod, Super-Sod ...
(Date:7/31/2015)... GA (PRWEB) , ... July 31, 2015 , ... ... five new industry players to know in predictive health analytics , Jvion ... learning technologies. The firm creates predictive software that targets patient and population level ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... at its new True North Conference Center. The medical community, social workers, law ... community may be more aligned in the effort to better understand and combat ...
(Date:7/31/2015)... ... , ... According to the article published July 27 on My News LA, a ... extinguished by the city’s fire department before it caused major damage throughout the building. The ... fire, and it was a fire alarm system that tipped off fire fighters so they ...
Breaking Medicine News(10 mins):Health News:March4thforWellBeing Foundation Kickoff 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3
Other Contents